Oncology CT

Targeted dose CT lung cancer screening does not have substantial effect on life-years saved among high risk groups.

Detecting clinically significant disease among PI-RADS category 3 lesions may be improved by incorporating clinical parameters into risk stratification algorithms.

Compared to standard biopsy strategy, MR imaging-guided strategies are cost effective in helping detect prostate cancer.

By adding a new category to lung CT reports, radiologists can identify more malignant lesions.

Direction from the Society of Nuclear Medicine & Molecular Imaging offers guidance for bone scintigraphy with patients who have prostate or breast cancer.

Multi-parametric MRI may be a substitute for serial biopsies in active surveillance regimens to avoid patient discomfort associated with repeat biopsies.

Annual low-dose CT screening for lung cancer for high-risk patients may not be necessary.

Inappropriate imaging for low-risk prostate cancer and low-risk breast cancer varies by region.

CMS released their final decision for lung cancer screening with low-dose CT.

NCCN Group 2 high-risk patients to benefit from CT lung screening, study says.

Patients who underwent low-dose CT for lung cancer screening and received false-positives benefited from counseling.

Low-dose CT lung cancer screening detects more early cancers in at-risk patients than radiography, but with lower positive predictive value.